Published in Am J Pathol on December 05, 2011
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes (2012) 1.10
Anandamide attenuates Th-17 cell-mediated delayed-type hypersensitivity response by triggering IL-10 production and consequent microRNA induction. PLoS One (2014) 0.87
Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis. Mol Med (2015) 0.87
Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol (2015) 0.82
Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. Proc Natl Acad Sci U S A (2014) 0.80
The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus. Adv Pharm Bull (2014) 0.78
Endocannabinoids in neuroendopsychology: multiphasic control of mitochondrial function. Philos Trans R Soc Lond B Biol Sci (2012) 0.77
Behavioral, Metabolic, and Immune Consequences of Chronic Alcohol or Cannabinoids on HIV/AIDs: Studies in the Non-Human Primate SIV Model. J Neuroimmune Pharmacol (2015) 0.77
Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation. PLoS One (2013) 0.76
Changes in plasma levels of N-arachidonoyl ethanolamine and N-palmitoylethanolamine following bariatric surgery in morbidly obese females with impaired glucose homeostasis. J Diabetes Res (2015) 0.76
Cardioprotective Potentials of Plant-Derived Small Molecules against Doxorubicin Associated Cardiotoxicity. Oxid Med Cell Longev (2016) 0.75
Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice. Clin Dev Immunol (2013) 0.75
Targeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis. World J Nephrol (2017) 0.75
Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. Sci Rep (2017) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49
Oxidative stress and diabetic complications. Circ Res (2010) 9.37
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care (2010) 6.64
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet (2006) 6.50
Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 6.36
Diabetic retinopathy. Lancet (2010) 5.38
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med (2005) 5.38
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov (2004) 3.47
The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil (2010) 3.20
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 3.02
Activation of the peripheral endocannabinoid system in human obesity. Diabetes (2005) 2.90
Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol (2005) 2.82
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol (2007) 2.81
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab (2006) 2.72
Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord (2010) 2.47
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res (2009) 1.99
Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest (1997) 1.95
Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol (2006) 1.77
CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol (2007) 1.77
Oxidative stress in diabetic nephropathy. Curr Med Chem (2010) 1.70
The endocannabinoid system in obesity and type 2 diabetes. Diabetologia (2008) 1.61
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol (2010) 1.56
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol (2007) 1.54
Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) (2008) 1.51
Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem (2010) 1.49
Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med (2009) 1.38
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs (2010) 1.34
Diabetes and the peripheral nerve. Biochim Biophys Acta (2008) 1.33
Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia (2007) 1.33
CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol (2007) 1.32
Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium (2006) 1.31
Endocannabinoid mechanisms of pain modulation. AAPS J (2006) 1.28
Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol (2008) 1.27
Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells. Diabetes (2011) 1.26
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med (2011) 1.24
Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther (2008) 1.24
CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol (2009) 1.24
Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation (2008) 1.24
The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol (2009) 1.24
CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res (2009) 1.22
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity (2006) 1.22
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes (2010) 1.21
The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol (2011) 1.21
Diabetic cardiomyopathy. Clin Sci (Lond) (2009) 1.18
CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol (2010) 1.18
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int (2007) 1.14
Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. J Neurosci (2008) 1.10
Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology (2007) 1.09
Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis (2010) 1.09
CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol (2010) 1.09
Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain (2010) 1.09
Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes (2011) 1.08
Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept (2007) 1.08
Endocannabinoids in the retina: from marijuana to neuroprotection. Prog Retin Eye Res (2008) 1.08
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med (2011) 1.05
Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care (2009) 1.04
Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch Biochem Biophys (1999) 1.01
Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol (2007) 1.01
Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med (2010) 1.01
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol (2010) 1.01
Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. Prostaglandins Leukot Essent Fatty Acids (2006) 1.01
The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett (2004) 0.99
Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs (2010) 0.98
Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int Immunopharmacol (2001) 0.97
Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol (2010) 0.97
Expression and function of cannabinoid receptors in mouse islets. Islets (2010) 0.96
Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem Biophys Res Commun (2008) 0.96
Cannabinoid receptors are coupled to stimulation of insulin secretion from mouse MIN6 beta-cells. Cell Physiol Biochem (2010) 0.95
The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology (2002) 0.94
Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line. Diabetologia (2011) 0.92
The cannabinoid CB1 receptor is expressed in pancreatic delta-cells. Biochem Biophys Res Commun (2008) 0.90
Role for cannabinoid receptors in human proximal tubular hypertrophy. Cell Physiol Biochem (2011) 0.88
CB1 cannabinoid receptor expression is regulated by glucose and feeding in rat pancreatic islets. Regul Pept (2010) 0.87
Hyperglycemia induces apoptosis via CB1 activation through the decrease of FAAH 1 in retinal pigment epithelial cells. J Cell Physiol (2012) 0.84
The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Res Cardiol (2009) 0.83
Effects of chronic treatment with the CB1 antagonist, rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats. Obesity (Silver Spring) (2009) 0.83
Retracted Cannabidiol protects retinal neurons by preserving glutamine synthetase activity in diabetes. Mol Vis (2010) 0.82
The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells. Neurobiol Dis (2007) 0.82
Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. Diabetes Care (2009) 0.82
Cannabinoid receptor 1 mediates palmitic acid-induced apoptosis via endoplasmic reticulum stress in human renal proximal tubular cells. J Cell Physiol (2010) 0.82
Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice. Eur J Pharmacol (2010) 0.82
Cannabinoid receptor 1 mediates high glucose-induced apoptosis via endoplasmic reticulum stress in primary cultured rat mesangial cells. Am J Physiol Renal Physiol (2011) 0.81
Functional blockage of the cannabinoid receptor type 1 evokes a kappa-opiate-dependent analgesia. J Neurochem (2007) 0.80
Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J Pharmacol Exp Ther (2007) 0.80
Cannabinoid CB(1) receptor activation stimulates neurite outgrowth and inhibits capsaicin-induced Ca(2+) influx in an in vitro model of diabetic neuropathy. Neuropharmacology (2009) 0.79
Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat. Eur J Pharmacol (2010) 0.79
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab (2008) 2.91
Activation of the peripheral endocannabinoid system in human obesity. Diabetes (2005) 2.90
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat Protoc (2007) 2.84
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol (2007) 2.81
Simple quantitative detection of mitochondrial superoxide production in live cells. Biochem Biophys Res Commun (2007) 2.51
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes (2006) 2.40
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 2.15
CD39 and CD73 in immunity and inflammation. Trends Mol Med (2013) 2.08
Evidence for novel cannabinoid receptors. Pharmacol Ther (2005) 2.00
Redox regulation of OxyR requires specific disulfide bond formation involving a rapid kinetic reaction path. Nat Struct Mol Biol (2004) 1.99
Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J Immunol (2005) 1.98
Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med (2002) 1.97
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J (2007) 1.94
Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology (2008) 1.90
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol (2009) 1.89
Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol (2004) 1.88
Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol (2008) 1.87
Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol (2009) 1.85
Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice. Hepatology (2010) 1.82
Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther (2006) 1.82
CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol (2007) 1.77
A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood (2007) 1.76
What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One (2011) 1.74
Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem (2003) 1.70
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol (2007) 1.68
Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure. Am J Physiol Heart Circ Physiol (2004) 1.67
Flagellin from gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock (2003) 1.64
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol (2010) 1.56
Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice. Am J Physiol Heart Circ Physiol (2008) 1.55
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol (2007) 1.54
Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation (2002) 1.52
Investigational A₃ adenosine receptor targeting agents. Expert Opin Investig Drugs (2011) 1.49
A(2B) adenosine receptors in immunity and inflammation. Trends Immunol (2009) 1.48
Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology (2015) 1.48
The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol (2003) 1.48
Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats. Crit Care Med (2003) 1.46
Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock (2002) 1.44
Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol (2006) 1.43
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol (2005) 1.42
Oxidative inactivation of key mitochondrial proteins leads to dysfunction and injury in hepatic ischemia reperfusion. Gastroenterology (2008) 1.42
Functional interaction between Smad, CREB binding protein, and p68 RNA helicase. Biochem Biophys Res Commun (2004) 1.40
Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol (2007) 1.39
Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J (2011) 1.38
Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med (2009) 1.38
Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic Biol Med (2011) 1.36
Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2007) 1.34
A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol (2010) 1.33
A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. J Pharmacol Exp Ther (2004) 1.32
Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med (2002) 1.31
Disruption of the actin cytoskeleton results in nuclear factor-kappaB activation and inflammatory mediator production in cultured human intestinal epithelial cells. J Cell Physiol (2004) 1.28
Adenosine receptor activation ameliorates type 1 diabetes. FASEB J (2007) 1.27
Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci (2005) 1.25
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med (2011) 1.24
Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther (2008) 1.24
G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. J Biol Chem (2003) 1.24
Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res (2002) 1.23
Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol (2007) 1.22
CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res (2009) 1.22